We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alizyme | LSE:AZM | London | Ordinary Share | GB0000374289 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.08 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 4.08 | GBX |
Alizyme (AZM) Share Charts1 Year Alizyme Chart |
|
1 Month Alizyme Chart |
Intraday Alizyme Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 31/7/2020 | 12:22 | -- (Moderated) The NEW Official Alizyme Thread: The Next Phase -- | 24,322 |
| 18/7/2012 | 08:26 | ALIZYME - THE TRACK RECORD SO FAR | 260 |
| 28/7/2009 | 12:48 | AZM Chart | 4 |
| 25/7/2009 | 10:57 | -- (Moderated) The NEW Official Alizyme Thread: STAYING ALIVE | 352 |
| 29/5/2008 | 12:24 | Let's Short This Duffer Out Of Business | 39 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 31/7/2020 11:38 by zzaxx99 Just had a blast from the past - a note from an account which I don't remember having, saying that the Alizyme shares which I'd forgotten about (or more accurately, had blanked out of my memory), had "made a distribution" of 0.3p per share.Wowee - now I can buy that boss guitar I'd always wanted. Or some picks, anyway |
Posted at 05/11/2019 13:16 by dr biotech Think I paid about c£1.30 total loss about £5k. Not life changing, but my worst ever investment. Taught me not to fall in love with a share and to remember that CEOs aren't always truthful. |
Posted at 28/4/2014 14:50 by mikepearce45 Thanks Mike for the update. I needed some good news after watching GKP and QPP share prices succumb to gravity! |
Posted at 27/4/2014 17:30 by mad mike I have only just come across AZM's Liquidator's reports dated 11-Feb-14 (on their web-site). For those that do not know, the important 'news' is litigation was settled last summer that had been holding up any possible realisation of assets for the benefit of shareholders.The Liquidator report says AZM shareholders will actually get something back for AZM their shares, though not immediately. Future dividend payments depend upon third parties' milestone/royalty payments. I believe there are around 217M AZM shares in issue, so it looks like every £1M of realised assets (after other creditors are paid off) would result in a shareholder payout of a little less than half a penny per share. The relevant section in the Liquidator's report is copied below. Also at the bottom there is a links to the Liquidator's Feb'04 reports:- "Shareholders [of Alizyme Plc] ~~~~~~~~~~~~ 3.5. It is anticipated that there will be sufficient funds for a distribution to be made to the Company's shareholders. As stated in the annual report of ATL, future milestone payments may be received in 2014, thus facilitating a further distribution to the Company. 3.6. Given the uncertainty surrounding potential further dividends to the Company, I am unable to provide any estimates as to the timing or quantum of a distribution to the shareholders. 3.7. There are approximately 4,500 shareholders in the Company, thus it is not cost effective to pay an interim dividend, but the position will be reassessed in one year's time." The Liquidator's 2013 annual reports for the following two companies can be found (n.b. these are different reports than those filed at Companies House):- hxxp://ww7.global3di - Alizyme Plc (the holding company that have the listed shares) - Alizyme Therapeutics Ltd (the subsidiary company holding the IPR & past activities). |
Posted at 18/2/2011 16:38 by the_doctor sorry mike, I should have said that I'd seen the tax credits stated in the docs you posted links to, but I was wondering if there was any tax asset against which profits could be offset ie. the tax losses.'I don't believe you can sell tax losses.' near enough confirms it then, thanks. I still dont quite see what represents a 3rd party and what doesnt in M&A ie. if someone reversed into AZM, could they use the tax losses? |
Posted at 18/2/2011 13:23 by dr biotech Cheers for the update MMYour'e right they can't sell on the tax losses to 3rd parties. Going back some time there was a paid for brokers note on CEN that counted the tax loss as an asset worth 25p a share or similar. I remember thinking this was riduculous and needless to say CEN got sold for a fraction of that. Shame they can't be sold really, I'd like to get back 30% of the money I've lost on various biodogs. |
Posted at 18/2/2011 12:00 by mad mike AZM/ATL have already received R&D tax credits, and are already in the assets I quoted.However it you really meant past tax losses (which would be huge), I believe you can only use such tax losses against future profits. Thus a profitable company would have to reverse into AZM/ATL to realises those past tax losses. Now that AZM/ATL are in liquidation I'm doubtful if anyone can reverse into them. FYI, I don't believe you can sell tax losses. |
Posted at 18/2/2011 10:47 by the_doctor Interesting mad mike - and sad for holders of course, although something back is better than nothing!Any idea how tax credits are dealt with? ie. AZM had presumably built quite a lot up. Did that have any value, or is it not transferrable in that way? |
Posted at 18/2/2011 10:31 by mad mike The liquidator's annual reports for Alizyme Plc, and its (important subsiduary) Alizyme Therapeutics Ltd can be found here:-On a quick read (based upon current assets only), it looks like the most any Alizyme shareholder would receive is around 1.6p per share (n.b. these are my quick calculations so may be wrong, so please DYOR). My figure is just based upon £3.5M approx in current assets (after allowing for unsecured creditors), and 221M AZM shares in issue. However, even to get that payment a substaintial legal claim against the company would have to fail. Until that claim is resolved there can be no payout to unsecured creditors, let alone any payout to shareholders. Thus the claim must be substantial and likely to be in excess, of current assets i.e. greater than £3.5M. Possibly the only good news is Cetilistat has completed Phase III in Japan, & there are currently discussions about getting Market authorisation there. By good news, I'm making the unproven assumption that the current owners of Cetilistat (Norgine B.V.) could be making some payment to Alizyme if Cetilistat starts to get sold in Japan. The Annual report also announces an AGM for shareholders and creditors at 10:30am on 17/2/11, at Grant Thornton, 30 Finsbury Sq, London EC2P 2YU. Prior permission needs to be agreed before attending - see detials in Annual Report. |
Posted at 10/7/2009 19:20 by troutfish I must join those once again having to correct VOWs comments and misrepresentations.CC and Optima have made it completely clear they are referring to a relist on AIM not the main market, as a possible option either very soon, or at the end of a period of Administration after Cetilistat Japan reports next year. A new quote on AIM costs £200,000 - £300,000, not £1 million like VOW says. Ongoing average costs of maintaing an AIM listing are £200,000 /year. This compares to ongoing costs of at least £300,000 - £400,000 /year for the main market. Typically companies on AIM have lower fees for nomads, auditors, lawyers and non-executive directors in view of lesser continuing obligations. Even if a Company delists completely from the Main Market and AIM there are secondary markets which allow trading on a matched bargain basis on which listing may cost very little (less than 10% of AIM). This (or AIM) could be an option although it might need a shareholder vote and there is no evidence of this in the AGM resolutions, just a hint of something in the Trading Update on 29/6/2009 about the main market listing: "The Company, with its advisers, is also considering the suitability of the Company's current main market listing given its market capitalisation and limited resources". I think any short-term move to reduce the listing costs would be welcomed, especially a move to AIM. P.S. Excellent posts from CC and Optima. '''''''''''''''''''' City Chappy - 10 Jul'09 - 09:03 - 158 of 162 A few thoughts. 1) If Alizyme go into Administration without significant debts the large shareholders might suggest to the Administrators the Company remains suspended in Administration until the Phase 3 Cetilistat Japan results are out next year or a deal is concluded sooner for ATL-104 (my assumption is the former, which would preserve more value for the Company and shareholders). Going into administration does not necessarily imply immediate liquidisation of assets! "An Administrators primary role is to rescue a Company as a going concern" - how true. If the Cetilistat results in 2010 are good the Company would receive a large milestone payment from Takeda and could then be requoted on AIM with the same number of shares as now, so preserving the holdings of all shareholders and giving big upside as the re-quoted price should be much higher. Further Cetilistat deals might then follow for other Asian and Pacific territories and the Company could progress ATL-104 through further trials. 2) Alternatively if current AGM resolutons 6 & 7 are approved, Alizyme might be able to place just enough shares to raise sufficient working capital (perhaps with any existing cash) to keep them quoted (probably on AIM and with minimal staff as now) until Cetilistat Japan reports next year or they can do a deal for ATL-104. Such a Placing would remove "going concern" fears and should result in a rise in the share price. 3) Even if the Company went into liquidisation, the assets of Cetilistat (e.g. Japan and maybe SE Asia) and ATL-104 appear to be worth more than the current market capitalisaton, so shareholders should get quite a lot back. (The share price is only now low because of "going concern" issues, not because the assets are are only worth the current share price). '''''''''''''''''''' Optima2 - 10 Jul'09 - 10:43 - 163 of 170 City Chappy good post. The large shareholders you mentioned in Point 1 also include outgoing CEO Tim McCarthy and his wife Susan (1,1080,000 shares) and directors like Sir Brian Richards. I think they would lobby any Administrators to hold off liquidisation and wait for the Cetilistat Japan results after next July which is not long, particularly as it is not unusual for companies to spend more than 12 months in Administration anyway. After then milestone cash from takeda should allow re-listing of Alizyme on AIM with the same number of shares as now and reappointment of Alan Goodman at the helm if he wanted the job. '''''''''''''''''''' Optima2 - 10 Jul'09 - 13:27 - 165 of 170 Obviously Administration involves delisting and i and CC did not imply otherwise. I just said the Administrators could re-list Alizyme [on AIM] after the Cetilistat Japan results in 2010 if it passed the trial because the Company would receive milestone cash from Takeda (even if delisted and in Administration) and subsequent sales royalties, making it a going concern again. You asked for examples of payouts to shareholders after Administration? - Shareholders often get payouts after Companies go into Administration and that is why some shareholders buy preference shares to increase their chances of such payouts. AZM do not have preference shares so all holders rank equally. - Ardana shareholders might get something back afterall even though it has taken 12 months: Use the same timeline for AZM and in 12 months (July 2010) Takeda will have completed Cetilistat Phase 3 in Japan and be about to release the pivotal Phase 3 results and potentially pay Alizyme a large milestone and future sales royalties. Administrators would have to take that into account together with opinions of shareholders (if offered) and any debtors on how to proceed. They might also decide they might out-license ATL-104 in the mean time and info posted here yesterday has shown that Amgen recently out-licensed Kepivance indicating there are partners out there for that type of drug. Remember the primary aim of Administrators is to keep a Company as a going concern. It is not to short-change shareholders or debtors, or to sell off the assets to the lowest bidder. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
